- 2024 mid-year budget proposed exempting active pharmaceutical inputs and finished products from VAT
- This exemption would likely reduce the cost of pharmaceutical products for consumers
- The goal is to make healthcare more affordable and accessible for the population
- This move could potentially boost the pharmaceutical industry and encourage more investment in the sector
Source: kpmg.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
